Key Takeaways
- Pathology review is a new specialist interpretation of source material. Translating the old report is useful, but it is not a pathology second opinion.
- Send the final report, every addendum, specimen and block identifiers, representative slides or digital images, and the clinical question. A report without the underlying specimen may limit what can be confirmed.
- Biomarker results must be tied to the tested specimen, method, date and disease context. A “negative” result may reflect specimen quality or assay limits as well as biology.[1]
- Laboratory trends need collection dates, units, reference ranges and the timing of treatment, transfusion or other interventions. Different laboratories may use different methods and ranges.[2]
- The treating team—not the courier or coordinator—decides whether review can safely delay treatment and which safety tests must be repeated after arrival.
Content
Treatment can depend on a single line in a report: the tumour type, margin status, receptor expression, a molecular alteration, renal function or a clotting result. The purpose of pre-treatment review is not to repeat every test. It is to establish whether the result being used is the right result, from the right patient and specimen, obtained by a suitable method at a clinically relevant time.
That requires two different reviews. A pathologist examines tissue or cells and interprets disease. The treating team and laboratory specialists then decide whether blood, urine or other laboratory results are current and comparable enough to support the planned therapy.
Start With the Decision the Result Must Support
Ask the receiving team to complete this sentence: “Before we can recommend or begin treatment, we need to confirm…”
Possible answers include:
- Whether the lesion is malignant and what type it is
- Grade, stage-related features or surgical margins
- Whether the submitted specimen is adequate for a required biomarker
- Whether a reported biomarker matches a particular treatment context
- Whether blood counts, kidney, liver or coagulation status permit treatment now
- Whether an abnormal laboratory result is persistent, treatment-related or technically suspect
This keeps the review proportional. A complete rework of all old testing may waste tissue, money and time; a review that omits the treatment-defining question is equally unhelpful.
What Belongs in a Pathology Review Packet
All report versions
Include the original-language preliminary report, final report and every addendum or amendment. File them separately and label their status. The newest page is not always a replacement; an addendum may supplement rather than cancel the main diagnosis.
Specimen identity
Record the patient name and identifier used by the original laboratory, accession or pathology number, collection date, specimen site and side, procedure type and reporting institution. The National Health Commission’s pathology guidance requires reports to include identifiers, specimen site, pathology number, diagnosis, reporting physician and time.[3]
Material available for review
Ask the reviewing laboratory exactly what it accepts:
- Stained glass slides
- Unstained slides
- Paraffin block or curls
- Cytology slides or cell block
- Flow-cytometry data
- Digital whole-slide images
- Molecular raw data or variant files, where useful
Do not send the only block until release, tracking, return and tissue-use terms are clear. Chinese guidance requires medical institutions to maintain systems for borrowing and consultation involving slides and smears.[3]
Clinical context
Provide a concise history, imaging site, prior therapy, operative note and the question being asked. A pathologist should not have to infer whether “lung lesion” means a primary lung tumour or possible metastasis from a prior cancer.
Report Translation Versus Pathology Re-Review
A translated report tells the Chinese team what the original pathologist wrote. A re-review asks another pathologist to evaluate the available slides, images or material and issue their own interpretation.
Both can be useful. They answer different questions.
For a re-review, ask whether the output will be:
- A confirmation of the submitted diagnosis
- A revised diagnosis
- A descriptive consultation with unresolved differential diagnoses
- A recommendation for additional stains, molecular testing or a new biopsy
NCI explains that a pathology second opinion may require slides and/or a paraffin block, and that patients should contact the reviewing institution about availability, costs and shipping requirements before sending material.[4]
When Two Pathologists Disagree
A discrepancy does not automatically prove negligence. Differences can arise from new slides, additional immunostains, evolving classification, specimen limitations or genuine interpretive uncertainty.
Ask the Chinese reviewer to identify:
- The exact point of disagreement
- Which slide, stain or criterion drives it
- Whether the difference changes treatment
- Whether another subspecialty review or test could resolve it
- Which report should be treated as current and how the original institution will be notified
Preserve both reports. Do not edit the first PDF to match the second. The treatment team needs the diagnostic history, including uncertainty.
Protect Limited Tissue
A small biopsy can be exhausted by repeated stains and broad sequencing. Before releasing a block or ordering more tests, ask:
- How much tumour is present?
- Which tests are essential for the next decision?
- Can existing slides or prior data answer the question?
- How many unstained sections are requested and at what thickness?
- Will the block be returned, and what material is expected to remain?
- Is a new biopsy clinically safer or more informative than consuming the old sample?
This is a clinical prioritisation decision. “Run every panel” is not automatically comprehensive care.
Read Biomarker Reports in Context
Biomarker testing may examine genes, proteins or other features to help select treatment, but it does not help every patient and results are a snapshot of one sample at one time.[1]
For each result, identify:
- Disease and treatment setting for which it is being considered
- Specimen type, site and collection date
- Tumour-cell content or other adequacy statement
- Method, platform and genes or markers covered
- Detected alteration and how it is reported
- Limit of detection and assay limitations
- Quality-control or failure comments
- Whether the result is pathogenic, likely pathogenic, uncertain or otherwise classified
- Which clinician or molecular team interprets treatment relevance
A variant of uncertain significance is not automatically a treatment target. A “no alteration detected” result does not prove that no relevant alteration exists if the panel was narrow, tumour content low or the specimen old. NCI notes that tissue can be insufficient, tests can find no actionable marker, and tumour biomarkers can change over time.[1]
Separate tumour (somatic) testing from inherited (germline) testing. A possible inherited finding may require confirmation in a suitable normal sample and genetics counselling; it should not be communicated to relatives as a confirmed hereditary diagnosis from tumour-only testing.
Build Laboratory Trends Without Inventing Comparability
For each treatment-relevant laboratory result, preserve:
- Collection date and time
- Test name
- Numeric or qualitative result
- Unit
- The reporting laboratory’s reference range
- Specimen type
- Fasting or timing condition when relevant
- Relationship to treatment, transfusion, dialysis, growth factor, steroids or another intervention
Reference ranges and methods can differ between laboratories. MedlinePlus cautions that a value outside a range may not by itself indicate disease, a value inside the range does not guarantee health, and results from different laboratories may not be directly comparable.[2]
Use a trend chart for orientation, but keep every source report. If units are converted, show both the original and verified converted value. Never paste values into a table without their units.
Old Results May Be True but No Longer Current
A six-week-old creatinine may accurately describe that day and still be unsafe for today’s contrast study. A blood count taken before chemotherapy cannot clear the next cycle. A coagulation test before anticoagulant adjustment may be obsolete.
Ask the treating team which tests must be repeated in China and how close to treatment they must be collected. Common domains include blood counts, electrolytes, kidney and liver function, coagulation, pregnancy testing, infectious-disease screening, blood type and treatment-specific monitoring—but the exact set depends on the patient and intervention.
Do not repeat a test solely because it is foreign. Repeat it because the method, identity, specimen, recency or treatment requirement makes repeat testing necessary.
Check for Identity and Specimen Mismatches
Before clinical interpretation, compare patient identifiers, accession numbers, collection sites and dates across:
- Pathology requisition and report
- Slide or block label
- Operative or biopsy note
- Imaging showing the sampled lesion
- Molecular and immunohistochemistry addenda
If a left-sided lesion is paired with a right-sided specimen or the accession number differs, stop. Ask the originating and reviewing laboratories to reconcile the chain before treatment relies on the result. A translated name-order difference may be administrative; it still requires documented resolution.
Shipping Is Part of Specimen Integrity
Obtain written packing, temperature, courier, customs and address instructions from both laboratories. Use tracked delivery and record every handoff. Slides break; blocks can soften in heat; biological materials may require permits or special packaging.
The patient should know:
- What was released and how many pieces
- Who packaged it
- Tracking number and recipient
- Date received
- What was consumed for testing
- What will be returned and when
Do not ask an ordinary travel coordinator to improvise cross-border tissue shipment.
Decide Whether Treatment Waits
The reviewing pathologist can state what is pending. The treating clinician decides whether the pending information is likely to change treatment and whether waiting is medically acceptable.
Ask for three dates:
- Expected receipt and adequacy check
- Expected preliminary or final review
- Latest clinically safe treatment decision point
For rapidly progressive disease or an urgent safety problem, the team may need to begin an appropriate treatment before every optional test is complete. Conversely, an irreversible or high-risk treatment should not proceed from an unresolved identity or diagnosis error merely to protect a travel schedule.
The Pre-Treatment Review Note
Request a short integrated note stating:
- Pathology diagnosis being used for treatment
- Specimen and report reviewed
- Material not available
- Important discrepancy or uncertainty
- Biomarkers confirmed and their limitations
- Laboratory results accepted and those repeated locally
- Remaining pending tests
- Whether any pending item can change the plan
- Named clinician responsible for the final treatment decision
This note turns a pile of reports into an auditable decision.
Medical disclaimer: Pathology and laboratory interpretation is case-specific. This guide does not determine which review or repeat testing is clinically necessary. Treatment timing and specimen use must be decided by qualified professionals with access to the full case.
Related Hospitals
Confirm that the named hospital has the relevant pathology subspecialty, accepts external slides or blocks, can perform the required tests and provides written receipt and return procedures.
Related Treatments
Cancer surgery, chemotherapy, targeted therapy, immunotherapy, transplantation and other high-risk treatments may depend on specific diagnostic and laboratory confirmation.
Related Guides
- How to Organise Medical Records Before Seeking Care in China
- How to Share CT, MRI and Other Imaging Files With a Chinese Hospital
- Getting a Cancer Second Opinion in China
- How to Request English-Language Medical Records in China
FAQ
Is translating my pathology report enough?
It may be enough for orientation, but it is not a pathology re-review. A second pathologist generally needs slides, a block or suitable digital material to independently assess the diagnosis.[4]
Must every patient repeat all laboratory tests in China?
No. The treating team should repeat tests when recency, method, identity, comparability or treatment protocol requires it—not simply because the original laboratory was abroad.
What if the biopsy block is very small?
Tell both teams before shipment. Ask them to prioritise tests, estimate remaining tissue and decide whether existing data or a new biopsy is preferable to exhausting the only block.
Does a negative molecular panel mean there is no target?
Not necessarily. Review panel scope, specimen adequacy, detection limits and timing. A negative result can be technically valid yet incomplete for the clinical question.[1]
Who decides whether treatment can start while results are pending?
The treating clinician, with input from pathology, laboratory and the relevant specialty team, should weigh how likely the pending result is to change care against the risk of delay.
Sources
- US National Cancer Institute: Biomarker Testing for Cancer Treatment
- MedlinePlus, US National Library of Medicine: How to Understand Your Lab Results
- National Health Commission: Guidelines for the Construction and Management of Pathology Departments
- US National Cancer Institute: Surgical Pathology Reports and Second Opinions
- National Health Commission: Provisions on the Management of Medical Records in Medical Institutions
- US National Cancer Institute: Tumor Markers
Hero Image Review
The original image is rejected. It shows a generic doctor explaining a care pathway and contains no pathology slides, specimen identifiers, laboratory data or review workstation. A replacement should show a pathologist and laboratory physician comparing labelled slides, a final report with non-readable fields and a trend chart, with no identifiable patient data or exaggerated technology.